Before the COVID-19 pandemic, the typical vaccine took more than five years to develop. Pfizer, Moderna and more than a half-dozen other biopharma companies raced from virus discovery to phase 3 testing of their COVID-19 vaccines in under a year, promising an end to the pandemic in 2021.
Now the industry is asking an important question: Can we take what we learned from COVID-19 vaccine successes and use it to speed up the development of other vaccines?
We’ll explore strategies for compressing timelines in vaccine R&D, preclinical research, clinical trials and manufacturing, with insight and advice from people who have been on the frontlines of COVID-19 vaccine development. And we’ll look at how these techniques are already enhancing vaccine development for a range of diseases, including HIV, respiratory syncytial virus and pneumonia.
- Forming partnerships with the government, contract research organizations and others without the red tape that can slow down development.
- Best practices for assessing long-term safety on a compressed timeline, including using preclinical testing to model safety, and designing post-marketing studies to track long-term results in human trial participants.
- Setting up a manufacturing and distribution infrastructure early in the development process and engaging regulators in that process to ensure a smooth transition from clinical testing to commercialization.